CD271 is a functional and targetable marker of tumor-initiating cells in head and neck squamous cell carcinoma by Uppaluri, Ravindra et al.




CD271 is a functional and targetable marker of
tumor-initiating cells in head and neck squamous
cell carcinoma
Ravindra Uppaluri
Washington University School of Medicine in St. Louis
James S. Lewis Jr
Washington University School of Medicine in St. Louis
et al
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Uppaluri, Ravindra; Lewis, James S. Jr; and et al, ,"CD271 is a functional and targetable marker of tumor-initiating cells in head and
neck squamous cell carcinoma." Oncotarget.5,16. 6854-66. (2014).
http://digitalcommons.wustl.edu/open_access_pubs/3318
Oncotarget6854www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 5, No. 16
CD271 is a functional and targetable marker of tumor-initiating 
cells in head and neck squamous cell carcinoma
Oihana Murillo-Sauca1,5,6, Man Ki Chung1,5,6, June Ho Shin1,5,6, Christina 
Karamboulas7, Shirley Kwok4, Young Ho Jung1,5,6, Richard Oakley1,5, James R. 
Tysome1,5, Lovisa O. Farnebo1,5,6, Michael J. Kaplan1,5, Davud Sirjani1,5, Vasu Divi1,5, 
F. Christopher Holsinger1,5, Chafeek Tomeh1,5, Anthony Nichols8, Quynh T. Le2,5, A. 
A. Dimitrios Colevas3,5, Christina S. Kong4,5, Ravindra Uppaluri9, James S. Lewis 
Jr.9,10, Laurie E. Ailles7 and John B. Sunwoo1,5,6
1 Division of Head and Neck Surgery, Department of Otolaryngology, Stanford University School of Medicine, Stanford, CA
2 Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA
3 Department of Medicine, Stanford University School of Medicine, Stanford, CA
4 Department of Pathology, Stanford University School of Medicine, Stanford, CA
5 Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 
6 Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA
7 Ontario Cancer Institute, University Health Network, Toronto, Canada
8 Department of Otolaryngology – Head and Neck Surgery, Victoria Hospital, Schulich School of Medicine and Dentistry, 
London, Ontario, Canada
9 Department of Otolaryngology – Head and Neck Surgery, Washington University School of Medicine, St. Louis, MO
10 Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO
Correspondence to: John B. Sunwoo, email: sunwoo@stanford.edu
Keywords: HNSCC, cancer stem cells, NGFR, p75NTR, cancer-initiating cell, CD44
Received: May 22, 2014 Accepted: July 26, 2014 Published: July 26, 2014
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT
Tumor-initiating cells (TICs) in squamous cell carcinoma of the head and neck 
(SCCHN) are best characterized by their surface expression of CD44. Although there 
is great interest in identifying strategies to target this population, no marker of these 
cells has been found to be functionally active. Here, we examined the expression of 
the purported marker of normal human oral epithelial stem cells, CD271. We show 
that CD271 expression is restricted to a subset of the CD44+ cells. Using xenograft 
assays, we show that the CD44+CD271+ subpopulation contains the most tumorigenic 
cells. Loss of CD271 function results in a block in the G2-M phase of the cell cycle and 
a profound negative impact on the capacity of these cells to initiate tumor formation 
in vivo. Incubation with recombinant NGF results in enhanced phosphorylation of Erk, 
providing additional evidence that CD271 is functionally active. Finally, incubation 
of SCCHN cells with antibody to CD271 results in decreased Erk phosphorylation 
and decreased tumor formation in vivo. Thus, our data are the first to demonstrate 
that CD271 more specifically identifies the TIC subpopulation within the CD44+ 
compartment in SCCHN and that this receptor is a functionally active and targetable 
molecule. 
INTRODUCTION
Squamous cell carcinoma of the head and neck 
(SCCHN) is one of the most common malignant 
neoplasms of the upper aerodigestive tract. While there 
have been some modest improvements in the treatment 
of advanced cases, recurrence rates are still as high as 30-
50% for tobacco-related SCCHN, and the therapy alone 
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– which includes a combination of surgery, chemotherapy, 
and radiation – often results in significant morbidity and 
long-term functional toxicity, negatively affecting critical 
functions such as speech and swallowing. 
Tumor-initiating cells (TICs) in solid tumors 
represent a subpopulation of cells that have the ability 
to propagate tumor formation in vivo and have been 
associated with recurrence of disease and poor clinical 
outcomes due to their metastatic capacity and resistance 
to conventional chemotherapy and radiation. In SCCHN, 
the hyaluronic acid receptor CD44 has reproducibly been 
shown to be a marker that can distinguish these cells from 
non-TICs [1]. Specifically, the CD44+ population has been 
shown to contain the TIC subpopulation, since purified 
CD44+ cells from heterogenous primary tumors are able to 
give rise to tumors much more readily in xenograft model 
systems compared to CD44- cells, and these xenograft 
tumors subsequently reproduce the original tumor 
heterogeneity observed in the primary tumor. Importantly, 
the CD44+ population has also been discovered to have a 
greater capacity to handle oxidative stress and, as such, 
is more radioresistant [2]. This population has also been 
shown to have a significantly greater ability to metastasize 
to regional lymph nodes in animal models [3], and patients 
whose tumors have greater percentages of CD44+ cells 
have a significantly poorer clinical outcome [4]. Thus, 
there has been a strong growing interest in identifying 
strategies to target these cells. However, the discovery of 
targetable functional molecules identifying the TICs in 
SCCHN has remained elusive.
In normal human oral epithelium, a subpopulation 
of cells with stem cell – like properties has been shown to 
express a cell surface molecule, designated as the CD271 
antigen [5, 6]. This molecule, also known as the low 
affinity nerve growth factor (NGF) receptor or p75NTR, is a 
neurotrophin receptor and a member of the tumor necrosis 
factor receptor superfamily. In the nervous system, it 
has critical functions in cell survival [7], differentiation 
[8], and migration [9] of neuronal cells . Recently, this 
molecule has been identified as a marker of TICs in human 
melanoma [10, 11], esophageal carcinoma [12, 13], and 
hypopharyngeal carcinoma [14]. In addition to being 
expressed in discrete cells within the basal layer of normal 
oral epithelium, CD271 is also expressed in oral dysplasia 
and oral squamous cell carcinoma [15]. Importantly, the 
increased expression of CD271 has been associated with 
a poorer clinical outcome in esophageal cancer [16, 17], 
hypopharyngeal cancer [14], and oral squamous cell 
carcinoma [15, 18].
In this study, we show that cells expressing CD271 
in human and mouse SCCHN comprise a distinct subset of 
the CD44+ cells and that these CD44+CD271+ cells possess 
the greatest tumor-initiating capacity in this malignancy. 
Further, our data demonstrate that this receptor is 
functional in SCCHN and that inhibition of CD271 has 
profound negative effects on SCCHN tumor-initiating 
capacity, providing evidence for the first functional and 
targetable molecule specific to TICs in this malignancy.
RESULTS
CD271 is expressed in the majority of head and 
neck SCC
We assessed the prevalence of CD271 expression in 
head and neck SCC by immunohistochemical staining of a 
tissue microarray (TMA) containing 283 specimens from 
primary tumors (Table 1). Overall, 71% of the tumors 
showed strong positive CD271 staining (representative 
staining shown in Supplemental Figure 1). No correlation 
was observed with a particular anatomic site or with 
clinical parameters, such as TNM staging and outcome. 
However, these specimens represent a heterogeneous 
collection of mucosal tumors, including those from the 
oral cavity, oropharynx, hypopharynx, and larynx. There 
were a higher percentage of CD271+ tumors among the 
oropharyngeal SCC group of tumors, the majority of 
which were human papilloma virus positive, but there was 
no statistically significant difference in CD271 expression 
by HPV DNA or p16 status (data not shown). 
Table 1: Expression of CD271 in human primary SCCHN samples measured by immunohistochemistry
 Oropharyngeal (%) Non-Oropharyngeal (%) Total (%)
CD271+ 154 (76) 47 (58) 201(71)
CD271- 48 (24) 34 (42) 82 (29)
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CD271 is expressed on a discrete subset of 
SCCHN cells that have the capacity to initiate 
tumors
The expression pattern of CD271 in SCCHN 
was interesting in that there was discrete expression of 
this receptor on a distinct subpopulation of cells in oral 
SCC. Among well-differentiated oral SCC tumors, the 
expression of CD271 was in the “basal” aspect of the 
malignant epithelium, which maintained polarity (Figure 
1A). This basal expression is consistent with what has 
been described in normal human oral epithelium among 
cells possessing stem cell – like properties [5]. In tumors 
that were more poorly differentiated, there was more 
disorganized expression of CD271, but the subpopulation 
that was positive for the receptor was still distinct and 
separate from the CD271- cells. This discrete expression 
pattern was also observed in dissociated primary tumor 
cells that were stained for CD44 and CD271 and analyzed 
by flow cytometry. Importantly, the CD271+ cells 
comprised a subpopulation among the CD44+ cells in 
these primary tumors, but there was no appreciable CD44-
CD271+ subpopulation (Figure 1A). A distinct CD271+ 
subpopulation of cells was also observed in cell lines 
derived from both mouse and human oral squamous cell 
carcinoma (Figures 1B and 1C).
Because CD271 has been associated with normal 
and cancer stem cell phenotypes, we assessed whether 
CD271+ cells had a greater capacity for tumor initiation 
in vivo. Specifically, we were interested in determining 
whether the CD271+ cells possessed the primary tumor 
initiating capacity among the CD44+ population and if 
the CD44+CD271+ cells represented the more specific 
TIC population in SCCHN. To test this, we sorted the 
CD44+CD271+ cells, CD44+CD271- cells, and CD44-
CD271- cells from primary human oral SCC specimens 
(Supplemental Figure 2) and implanted them into the 
flanks of immunodeficient Rag-/-γc-/- mice in a limiting 
dilution fashion. Overall, the CD44+ cells had greater 
Figure 1: CD271 is heterogeneously expressed in SCCHN and marks the more tumorigenic population of cells. (A) 
Human primary SCCHN samples were stained with a monoclonal antibody against CD271 and assessed by immunohistochemistry and 
flow cytometry. The FACS plot is gated on the DAPI-lineage- population and co-stained for CD44 and CD271. (B) Two murine cell lines 
derived from oral tumors arising from DMBA-treated oral cavity mucosa were stained with a monoclonal antibody specific for murine 
CD271 and assessed by FACS. (C) Human cell lines derived from head and neck SCC were assessed for CD271 expression by FACS after 
staining with a monoclonal antibody to CD271.
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capacity to form xenograft tumors compared to the CD44- 
cells, but when low numbers of cells were injected, it was 
clear that the CD44+CD271+ cells had the greatest capacity 
to form tumors among these three populations (Table 
2); The tumors that formed in mice implanted with the 
CD44+CD271+ cells recapitulated the heterogeneity seen 
in the parental tumor (Supplemental Figure 3). Similarly, 
when mouse oral SCC cell lines (which were uniformly 
CD44+, data not shown) were sorted into CD271+ and 
CD271- populations, the CD271+ cells had significantly 
greater capacity to form tumors in vivo compared to 
the CD271- cells(Table 2). Thus, in SCCHN, the TIC 
population is marked by the expression of both CD44 and 
CD271.
Knockdown of CD271 in SCCHN inhibits cell 
proliferation and tumor formation
As with primary head and neck SCC, the expression 
of CD271 in human SCCHN cell lines was heterogeneous 
(Figure 1C). Among the four SCCHN cell lines that we 
examined, there were varied percentages of CD271+ 
cells. Although these cell lines had similar growth 
characteristics in vitro, implantation of the two lines with 
the highest percentages of CD271+ cells in mice resulted in 
the most robust in vivo tumor growth (Figure 2A). Because 
CD271 has been shown in other systems to modulate 
cell proliferation and survival [19-22], we investigated 
whether or not CD271 loss-of-function would have an 
effect on cell proliferation and tumor initiation. To do 
this, we expressed validated shRNA molecules targeting 
CD271 in SCCHN cells by lentiviral transduction. The 
knockdown of CD271 significantly affected cell growth 
in vitro (Figure 2C). In an MTT assay, the CD271hi cell 
lines (UPCI:SCC-103 and PCI-13), that were transduced 
with the CD271 shRNA, grew significantly more slowly 
compared to controls. This growth was rescued by co-
transducing the coding sequence for CD271, which lacked 
the 3’-UTR targeted by the shRNA (Figure 2D); thus, the 
reduced growth conferred by the shRNA was specific for 
CD271. Mechanistically, this appears to be due to a partial 
cell cycle block in the G2-M transition and not apoptosis 
(Figure 2E and Supplemental Figure 4). Thus, for cells 
expressing CD271, the receptor appears to be required for 
cell cycle progression.
To assess if CD271 expression also affected tumor 
initiation and growth in vivo, the PCI-13 oral SCC cell 
line, which was uniformly CD271+, was transduced with 
either a lentivirus that co-expressed the CD271 shRNA 
Table 2: Xenograft tumor formation with sorted population of human and mouse SCCHN cells
Human Primary Head and Neck SCC Tumor #1
Cells Injected 50,000 5,000 500
CD44-CD271- 0 of 2 0 of 6
CD44+CD271- 2 of 2 5 of 6 0 of 6
CD44+CD271+   3 of 5
Human Primary Head and Neck SCC Tumor #2
Cells Injected 100,000 10,000 1,000 100
CD44-CD271- 2 of 2 5 of 6 4 of 6
CD44+CD271- 2 of 2 8 of 8 7 of 8 4 of 8
CD44+CD271+ 2 of 2 8 of 8 8 of 8 8 of 8
Mouse Oral SCC Cell Line: MOC2
Cells Injected 10,000
CD271- 0 of 5
CD271+ 3 of 5 
Mouse Oral SCC Cell Line: MOC10
Cells Injected 10,000
CD271- 0 of 5
CD271+ 3 of 5 
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and mCherry or a lentivirus expressing GFP. The two sets 
of transduced cells were mixed at a 1:1 ratio and then 
injected into immunodeficient Rag-/-γc-/- mice (Figure 3). 
The tumors that formed were subsequently dissociated 
into single cells and analyzed by FACS, after excluding 
any infiltrating mouse cells (stained for mouse MHC class 
I). The tumors were found to be highly enriched for GFP+ 
cells even though the cells that were injected were initially 
50% mCherry+ and 50% GFP+ (Figure 3B). This was the 
case only when the CD271 shRNA was co-expressed in the 
mCherry construct. If a an mCherry control lentivirus was 
used, the resulting tumor remained approximately 50% 
mCherry+ and 50% GFP+. Thus, knockdown of CD271 
resulted in cells that were significantly less tumorigenic 
compared to control cells in the same microenvironment, 
indicating that CD271 is a functional receptor expressed 
on the tumor-initiating population in SCCHN.
Figure 2: CD271 loss-of-function results in decreased cell cycle progression in SCCHN. (A) Four cell lines derived from 
human SCCHN were assessed for in vitro growth kinetics by MTT assay and for in vivo tumor formation and growth by implantation 
into the flanks of Rag-/-γc-/- mice. (B) Knockdown of CD271 in human SCCHN cell lines by shRNA lentiviral constructs was assessed by 
FACS. (C) Effects of CD271 knockdown by shRNA expression on cell proliferation was assessed by MTT assay. In the cell lines with 
high expression of CD271 (UPCI:SCC-103 and PCI-13), there was a decrease in cell viability at the end of the MTT assay. Two different 
shRNAs were assessed: “sh3” = CD271 shRNA3. “sh5” = CD271 shRNA5. (D) The effects of the CD271 knockdown was reversed by 
co-expression of the CD271 coding sequence that lacked the 3’-UTR, which was targeted by the shRNA. In the FACS plots, the rescued 
expression of CD271 is demonstrated in the plot on the right. The bar graph represents the fold change in cell viability at the end of an MTT 
assay (relative to day 0). “c” = empty vector control or scramble RNA control. “p75”= CD271 coding sequence lacking the 3’-UTR. “sh3” 
= CD271 shRNA3. “sh5” = CD271 shRNA5 *p<0.01, **p<0.005. (E) PCI-13 cells were transduced with lentivirus expressing CD271 
shRNA3, CD271 shRNA5, or a scrambled control RNA. Percentages of cells in the various phases of the cell cycle were assessed by FACS 
after staining with BrdU and PI; these percentages are quantified in the bar graph. *p<0.01.
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Targeting CD271 with a monoclonal antibody 
inhibits in vivo tumor formation by SCCHN cells 
and inhibits phosphorylation of Erk
The inhibition of in vivo tumor formation with 
CD271 loss-of-function suggested that this molecule 
might be a viable therapeutic target in SCCHN. To 
address this hypothesis, we targeted the receptor with 
a monoclonal antibody specific for NGFR. Incubation 
of PCI-13 SCCHN cells with the antibody resulted in a 
significant reduction in cell proliferation in vitro compared 
to cells treated with isotype control IgG (Figure 4A). 
Furthermore, treatment of the cells with the anti-NGFR 
antibody resulted in significant reduction in tumor growth 
in vivo compared to isotype control – treated cells. 
CD271/NGFR activation has been previously 
shown to work through downstream activation of both 
the MAP kinase and PI3 kinase pathways [23]. To 
determine the functional role of CD271 in SCCHN, we 
treated PCI-13 cells with recombinant human NGF in 
vitro and assessed activation of the MAP kinase pathway 
(Figure 4B). NGF treatment resulted in an increase in 
Erk phosphorylation detected by Western immunoblot. 
Furthermore, preincubation with the monoclonal antibody 
to CD271 abrogated this increase in Erk phosphorylation. 
There was, however, no apparent effect on the PI3 kinase 
pathway since p-Akt was not affected (data not shown). 
Our data indicate that CD271/NGFR is functionally active 
in SCCHN and that targeting CD271 with a monoclonal 
antibody is a potential therapeutic strategy in this cancer.
DISCUSSION
In this study, we extend the current understanding 
and characterization of TICs in SCCHN. We demonstrate 
that among the CD44+ cells in SCCHN, the CD44+CD271+ 
cells are the more specific TIC population. In addition, 
we show that CD271 is a functional cell surface molecule 
that responds to NGF ligand activation and signals through 
the MAP kinase pathway. CD271 loss-of-function in 
Figure 3: CD271 loss-of-function results in decreased tumor initiation in vivo. (A) Schematic of in vivo competition assay. 
PCI-13 cells were transduced with either a lentivirus co-expressing shRNA targeting CD271 and mCherry or a lentivirus expressing 
Zsgreen. Cells were mixed 1:1 and injected into the flanks of Rag-/-γc-/- mice. Cell composition in tumors arising in these mice was assessed 
by FACS analysis of cells from dissociated tumors. (B) FACS analysis of input cells at time of implantation and cells from dissociated 
tumors at the termination of the experiment. The bar graphs depict the percentages of mCherry and Zsgreen expressing tumor cells from 
each cohort of recipient mice. 
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these tumor cells results in a significant decrease in their 
capacity for tumor initiation, and targeting CD271 with 
a monoclonal antibody results in the inhibition of tumor 
growth in vivo. Thus, our data provide rationale for the 
targeting of CD271 as a therapeutic strategy.
Our data are consistent with the idea that the TIC 
population originates from a deregulated normal stem cell 
population. In normal human oral epithelium, a CD271 
expressing subpopulation of cells in the basal layer has 
been shown to have a stem cell – like phenotype [5]. 
These CD271+ cells have a greater proliferative capacity, 
form colonies more robustly in vitro, and form layers of 
cells expressing more differentiated markers, resembling 
stratified epithelium when cultured on amniotic 
membranes. Furthermore, the incubation of the CD271+, 
but not CD271-, cells, isolated from normal human oral 
epithelium, with NGF resulted in enhanced proliferation. 
Because CD44 is expressed in the basal half of the oral 
epithelium, CD271+ cells comprise a subset of the CD44+ 
cells in normal epithelium, similar to what we have found 
in SCCHN. Thus, it is likely that the CD44+CD271+ cells 
in SCCHN retain many of the stem cell – like properties 
of this subpopulation in normal epithelium. 
Interestingly, not all of the SCCHN tumors express 
CD271. This heterogeneity between SCCHN tumors 
indicates that in some tumors, the TIC population is 
marked by CD271, but in other tumors, the TIC population 
may be completely different phenotypically. This may 
reflect a different cell of origin for the TIC population 
in CD271+ tumors compared to CD271- tumors. It is 
possible that inciting mutation(s) can occur at different 
stages of epithelial differentiation and that, consequently, 
the markers identifying the resulting TIC subpopulation in 
SCCHN may be different. 
Interest in specific strategies to target the TIC 
population has been gaining traction in recent years with 
increasing evidence that these cells are more resistant to 
conventional chemotherapy and radiation therapy in a 
number of cancer types [24]. In SCCHN, there is evidence 
that the CD44+ population is able to handle oxidative stress 
better than the CD44- population and that the CD44+ cells 
are enriched after SCCHN xenografts are treated in vivo 
with radiation [2]. Our data would suggest that in CD271+ 
SCCHN tumors, the CD44+CD271+ cells would comprise 
the population most resistant to radiation-induced 
oxidative stress. Supporting this hypothesis is evidence 
that neurotrophins can increase tolerance of PC12 cells 
to reactive oxygen species in a CD271-dependent manner 
Figure 4: Targeting of CD271 with monoclonal antibody inhibits tumor formation and NGF-induced Erk 
phosphorylation. (A) PCI-13 cells were incubated with either azide-free monoclonal antibody specific for CD271 or isotype control IgG 
for 30 min, washed, and then assessed for cell proliferation in vitro and tumor growth in vivo. The graph on the left shows MTT cell viability 
results over 8 days, expressed as fold-change from the day 0 baseline. The graph on the right shows tumor growth from cells injected 
subcutaneously into the flanks of Rag-/-γc-/- mice. Each cohort consists of 4 mice. Experiments were performed at least two times. (B) PCI-
13 cells (grown in serum-free medium for 24 hrs) were incubated in vitro with monoclonal antibody to CD271 or isotype control IgG for 30 
min and then with or without recombinant human NGF for 1 hr. Cell lysates were subjected to gel electrophoresis, and Western immunoblot 
analysis was performed with antibody specific for phosphorylated-Erk (p-Erk1/2), total Erk, and actin. All experiments performed two or 
more times.
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[25]. Indeed, in esophageal squamous cell carcinoma, 
the CD271+ cells have been demonstrated to be more 
resistant to cisplatin, which like radiation, exerts its 
cytotoxic activity in part through oxidative stress [12, 26]. 
Since both cisplatin and radiation are mainstay treatment 
modalities in SCCHN, future work will be focused on 
assessing the ability of CD271 inhibition to enhance 
chemoradiation sensitivity of these CD44+CD271+ TICs.
Multiple studies have observed a correlation 
between the percentages of TICs, or cancer stem cells, 
within primary tumors and clinical outcome. In SCCHN, 
the percent of CD44+ cells has been correlated with 
regional metastatic recurrence [4]. Our data, together with 
what has been observed in esophageal carcinoma [16, 
17], hypopharyngeal carcinoma [14], and oral carcinoma 
[15, 18], would suggest that the percent of CD44+CD271+ 
cells might also provide prognostic information. One of 
the significant adverse features seen with some SCCHN 
tumors is perineural invasion (PNI), which has been 
associated with local recurrence and metastases [27]. 
Since Schwann cells around neurons and epithelium 
rich in neurons express NGF [28, 29], it is possible that 
expression of CD271 may predispose tumor cells to PNI. 
Indeed, in malignant melanoma, expression of CD271 
has been associated with PNI [30], and in oral cancer and 
pancreatic cancer [31-33], the expression of NGF has also 
been associated with PNI. In our set of SCCHN samples 
examined on the TMA, we did not observe an association 
between CD271 expression and PNI as recorded from 
pathology reports (data not shown). However, our set 
consisted of a heterogeneous group of head and neck 
tumor sites, and further examination of this is needed.
Our data that CD271 signals through the MAP 
kinase pathway in SCCHN is the first description of 
an actively signaling receptor that marks TICs in this 
malignancy. Although CD271 has also been described 
to signal through the PI3 kinase pathway [34], we did 
not observe any alterations in Akt phosphorylation with 
activation or inhibition of CD271 (data not shown). The 
feasibility of targeting CD271 to affect the viability of 
CD44+CD271+ cells in SCCHN and their capacity for 
tumor initiation is demonstrated by our study. In addition 
to targeting these cells with monoclonal antibody therapy 
in vivo, it will be interesting to see if MEK inhibition in 
these cells can also specifically reduce their viability and/
or sensitize them to cisplatin or radiation.
METHODS
Formalin Fixed Paraffin-Embedded Tissue 
Microarray
The tissue microarray (TMA) containing 283 
specimens from patient primary tumors was constructed 
as previously described [35, 36]. These specimens 
represented a heterogeneous collection of oropharyngeal 
(tonsil and base of tongue) and non-oropharyngeal 
(including sites from the oral cavity, hypopharynx, and 
larynx), retrospectively identified in pathology hospital 
files.  All cases got two punches from areas of tumor 
that were designated by the study pathologist (JSL) with 
a dotting pen on the original H&E slides.  According to 
the amount of available biopsied or resected tumor tissue, 
duplicate two millimeter (or if inadequate tumor tissue 
present, 0.6 millimeter) punches were taken from each 
case.  Since most of the cases (75%) were treated with 
primary surgery, the majority of cases on the array had 
the larger (two millimeter) punches. For the oropharyngeal 
SCC patients, DNA in situ hybridization for high risk 
human papillomavirus and p16 immunohistochemistry 
had been previously performed on whole tissue sections, 
as previously described [37]. CD271 expression was 
assessed by the study pathologist (JSL) visually and 
considered simply as a binary result: positive = any tumor 
cell staining and negative = no tumor cell staining. 
Mice and Cell Lines
Female Rag2-/-γc-/- mice (6-12 weeks old) in a Balb/c 
background were a kind gift from Dr. Irving L. Weissman 
(Stanford) and were bred in our animal facility under 
specific pathogen-free conditions. All animal procedures 
were conducted under institutional guidelines that comply 
with national laws and policies. The human HNSCC cell 
line UM-SCC-6 was obtained from Dr. Thomas Carey 
at the University of Michigan. The  oral SCC-4 cell line 
was obtained from ATCC. The  oral oUPCI:SCC103 
and PCI-13 cell lines were kind gifts from Dr. Suzanne 
Gollin Theresa Whiteside and Dr. Jennifer Grandis at 
the University of Pittsburgh. Cells were maintained in 
complete DMEM:F12 medium (DMEM:F12 1:1 with 
Glutamax [Gibco, Invitrogen, CA] containing: 10% heat-
inactivated FBS [Cellgro, MA], 100 IU/ml penicillin 
and 100 μg/ml streptomycin [Gibco, Invitrogen, CA]). 
The HEK293T cell line was obtained from ATCC and 
maintained in complete DMEM medium. The MOC2 and 
MOC10 murine oral SCC cell lines were developed by Dr. 
Ravindra Uppaluri at Washington University [38].
Antibodies
Monoclonal antibodies to CD31 (WM-59), CD45 
(30-F11), CD44 (G44-26), CD271 (C40-1457) for flow 
cytometry and sorting were obtained from BD Biosciences. 
Antibody to mouse CD271 (mu p75) was obtained from 
Advanced Targeting Systems. Antibody to fibroblasts 
(TE-7) was obtained from Millipore. Anti-mouse H-2Kd 
antibody (SF1-1.1) was obtained from BD Biosciences. 
Antibody to CD271 (NGFR5) for immunohistochemistry 
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and blocking experiments was obtained from Abcam and 
Thermo Scientific. Antibodies to phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204) (E10) and total Erk were 
obtained from Cell Signaling Technologies. Antibody to 
actin was obtained from Thermo Scientific.
Tumor Digestion and In Vivo Xenograft Assays
Patient tumor samples were obtained fresh from 
the operating room after a consenting process that was 
approved by the Institutional Review Board. Tumor 
cell dissociation was performed, as follows. Briefly, 
tumors were minced and then digested with collagenase-
hyaluronidase (Stem Cell Technologies) for 16 hrs at 37 
deg C. Following this, the cells were treated for 3 min with 
trypsin-EDTA, washed, treated with dispase and DNase I 
(Stem Cell Technologies) for 1 min, washed, filtered, and 
resuspended in PBS or FACS buffer. 
For in vivo xenograft assays, female Rag2-/-γc-/- 
mice were injected subcutaneously with the indicated 
number of viable cells, after cell dissociation, washing, 
and suspension in PBS. Tumor growth was monitored 
twice a week and tumor diameters were measured using 
an electronic calliper to determine the tumor size by 
multiplying perpendicular diameters. 
Quantitative RT-PCR
The relative abundance of p75NTR mRNA was 
analysed by quantitative real-time reverse transcription-
Polymerase Chain Reaction (RT-PCR) of SCC-4, UM-
SCC-6, UPCI:SCC-103 and PCI-13 cells. Briefly, cell 
cultures were rinsed with ice-cold PBS and then the cells 
were lysed and scraped off using Trizol (Invitrogen). 
Afterwards, chloroform (Sigma) was added and the 
mixture was centrifuged. RNA was recovered from 
the aqueous phase by precipitation with 2-propanol. 
The extracted RNA was treated with Turbo DNase to 
remove genomic DNA prior to reverse transcription with 
Superscript III Reverse Transcriptase (Invitrogen). Finally, 
real-time RT-PCR was performed using a specific Taqman 
Assay for the human p75NTR sequence. Human HPRT1 
was amplified as control. The amount of p75NTR mRNA 
was expressed as arbitrary units defined as the n-fold 
difference relative to the control gene HPRT1 (2ΔCt ×100, 
where ΔCt represents the difference in threshold cycle 
between the control and target genes). 
Lentiviral Plasmids
The lenti-vectors pLKO.1 puro and pLKO.1 
mCherry were kind gifts from Dr. Alejandro Sweet-
Cordero (Stanford). The following shRNAs against 
p75NTR were AgeI/EcoRI inserted into the pLKO.1 vectors: 
shp75NTR1(5’CCGGGCAC TGTAGT AAATGGCA 










The lentiviral constructs pHIV-Zsgreen and pHIV-
mCherry were kind gifts from Dr. Michael Clarke 
(Stanford). A cDNA from the ATG codon to the stop 
codon of human p75NTR was PCR cloned (forward primer: 
5’CATTAGCGGCCGC ACCATGGGGGCAGGTGCC-3’; 
reverse primer:5’CTGGTCTAGATCACACC 
GGGGATGTGGCAGTG-3’) and NotI/XbaI inserted into 
the pHIV-Zsgreen vector. 
Lentiviral production
For the production of the lentiviral particles, the 
cell line HEK293T was transfected, using CaCl2, with the 
packaging plasmid pCMV-dR8.2, the envelope plasmid 
pCMV-VSVG and the lentiviral construct containing the 
shRNA or the transgene. Cell culture medium was changed 
16 hours after the transfection and virus supernatants 
were collected 24 and 48 hours after the media change. 
Immediately after supernatant collection, the viral 
particles were concentrated by ultracentrifugation. The 
lentiviral pellets were then resuspended in ice-cold PBS 
and the virus was titrated by FACS using HEK293T 
cells. To calculate the biological titer of the virus, the 
following formula was used: TU/μl = (P × N/Vx100) 
× 1/DF, where TU stands for Transducing Units, P = % 
Zsgreen+ or mCherry+ cells, N = number of cells at time 
of transduction = 10^5, V= volume of dilution added to 
each well = 20 μl, and DF = dilution factor = 1 (undiluted), 
10^−1 (diluted 1/10), 10^−2 (diluted 1/100), and so on.
Lentiviral transduction
For the lentiviral transduction of the cell lines, cells 
were harvested, washed, resuspended in fresh medium 
and plated at the appropriate concentration (1x106 cells 
per 10 cm plates). Then, the lentiviral particles were added 
to the cell cultures at a multiplicity of infection (MOI) of 
1 transducing Unit per cell. Polybrene (8ug/ml) was also 
added to enhance the lentiviral transduction efficiency. 
48 hours after viral infection, medium was changed. In 
the case of the cells transduced with the pLKO.1 puro 
vectors, the cell cultures were treated with the selection 
agent puromycin for 3 days after media change.
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XTT and MTT Assays
The XTT and MTT assays were carried out 
following the manufacturer’s instructions (Roche Applied 
Science, Germany). Briefly, FACS-sorted cells were 
seeded into 96-well plates at a concentration of 500 to 
1500 cells per well in 100ul of culture medium. The XTT 
labelling mixture was added to the wells at different time 
points and incubated for 20 hours at 37 C before reading 
the plate in an ELISA reader at a wavelength of 450-500 
nm. For the MTT assays, MTT labelling reagent was 
added to the wells first. Then the plates were incubated for 
4 hours at 37 C and finally the solubilisation buffer was 
added to the wells and incubated at 37C for another 16 
hours before evaluating the plate in an ELISA reader at a 
wavelength of 550-600nm.
CD271 Rescue Experiment
To validate the selectivity of the shRNAs 3a and 
5a for p75NTR gene, a rescue experiment was performed 
employing an expression construct containing a p75NTR 
cDNA that was resistant to the shRNAs. Briefly, PCI-13 
cells were transduced first with the lenti-vector pHIV-
Zsgreen containing the cDNA of human p75NTR that lacked 
the 3’UTR region. 5 days after transduction, Zsgreen+ cells 
were sorted out by FACS. Afterwards, these cells were co-
transduced with the shRNAs 3a or 5a that were designed 
to the 3’UTR region of p75NTR mRNA. 5 days later, cells 
were FACS-sorted again based on the expression of 
Zsgeen and mCherry. The double-sorted cells were then 
plated into 96-well plates (500-1500 cells per well) to 
carry out a XTT or MTT assay. 
In vivo Tumor Growth Competition Assay
For the competition assay, the cell line PCI-13 was 
transduced with the lentiviral construct pHIV-Zsgreen 
(green) or with the lenti-vector pLKO.1 mCherry (red) 
containing or not the specific shRNAs against p75NTR 3a 
and 5a. Two days later, the culture medium was changed 
and five days after the viral transduction, the cells were 
harvested and washed twice with ice-cold PBS. The single-
cell suspensions were then FACS-sorted based on the 
expression of the reporter molecules Zsgreen (green) and 
mCherry (red). The double-sorted red and green cells were 
mixed in similar amounts and injected subcutaneously into 
immunocompromised Rag2-/-γc-/- mice. The tumors that 
arose in those mice were harvested when they reached 1.5 
cm in diameter and were dissociated using collagenase-
hyaluronidase from StemCell Technologies following 
the manufacturer’s instructions. Finally, the dissociated-
tumors were analysed by flow cytometry.
Flow Cytometry Analysis
Cells were harvested from culture flasks or isolated 
from mouse xenografts after tumor dissociation, as 
described above. Single-cell suspensions were then pre-
treated with IgG from mouse serum to block non-specific 
staining and incubated with the appropriate antibodies. 
DAPI was used to allow exclusion of non-viable cells; 
in the case of mouse xenografts, anti-mouse H-2Kd FITC 
antibody (SF1-1.1) was added to exclude mouse cells 
from the analysis. Then, CD44 and CD271 expression 
was assessed after exclusion of lineage+ cells (CD45+ cells, 
CD31+ cells, and TE-7+ fibroblasts).
To determine the percentage of cells within the 
PCI-13 cell line that were actively undergoing apoptosis 
after p75NTR knock down, the FITC Annexin V Kit from 
BD Pharmingen was used following the manufacturer’s 
instructions. Briefly, cells were washed twice in ice-
cold PBS and resuspended in 1x binding buffer at a 
concentration of 1x106 cells/ml. The cells were then 
incubated in the presence of Annexin V and PI for 15 
minutes at room temperature in the dark. After the 
15-minute incubation, 400ul of 1x binding buffer was 
added to each tube and the samples were analysed within 
1 hour.
Cell Cycle Analysis
For the cell cycle analysis, the oral squamous cancer 
cell line PCI-13 was transduced with lentiviral vectors 
carrying the specific shRNAs against p75NTR shRNA 3a 
or shRNA 5a or with the empty lenti-vector pLKO.1. 
puro. Two days after the viral transduction, the selective 
agent puromycin was added to get rid of the untransduced 
cells. After 3 days in the presence of the selection drug, 
the medium was changed and BrdU was added to the cell 
cultures for 4 hours. After the 4-hour incubation, the cells 
were harvested and washed with PBS twice to remove the 
non-incorporated BrdU. Then the BrdU labelled cells were 
fixed with 70% ethanol and kept at -20 degrees for at least 
2 hours. The day of the experiment, the cells were thawed 
and rehydrated in PBS for 15 minutes. DNA was denatured 
by adding drop-wise a solution containing 2M HCl and 
0.5% of Triton-X100. After a 20-minute incubation, the 
acid solution was neutralized using 0.1M sodium borate 
at pH 8.5. Finally, the samples were incubated in the 
presence of anti-BrdU FITC antibody (BD Pharmingen) 
for 30 minutes, washed and added a solution containing 
PI and RNase A just before they were analysed by FACS.
Targeting CD271 in vitro and in vivo
PCI-13 cells were incubated with either azide-free 
monoclonal antibody specific for CD271 (clone NGFR5, 
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Abcam, 5 ug/ml) or azide-free isotype control IgG (BD 
Biosciences, 5 ug/ml) for 30 min, washed, and then 
assessed for cell proliferation in vitro and tumor growth in 
vivo. The in vitro MTT cell viability results were assessed 
over 8 days and expressed as fold-change from the day 0 
baseline. For the in vivo tumor growth assessments, cells 
were injected subcutaneously (100,000 cells per mouse) 
into the flanks of Rag-/-γc-/- mice. Each cohort consisted 
of 4 mice. The experiments were done a minimum of two 
times. 
Western Immunoblot
PCI-13 cells were incubated with serum-free 
DMEM medium for 24 hrs. The cells were incubated 
with either monoclonal antibody to CD271 (NGFR5, 
Thermo Scientific) for 30 min and then, incubated with 
recombinant human NGF (Shenandoah Biotechnology, 
Inc.) for 1 hr. Whole cell lysates were collected, and 
proteins were separated by gel electrophoresis. Western 
analysis was performed with phospho-Erk, total Erk, and 
actin antibodies, described above.
Statistical Analysis
Prism software (Graph Pad Software, Inc.) was 
used to analyse tumor growth, cell viability, cell cycle, 
apoptosis and for the competition analysis in vivo and 
to determine statistical significance of the differences 
between groups by applying unpaired Student’s t-tests or 
U-Mann Whitney tests. P values of <0.05 were considered 
significant.
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